S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20

Compare Stocks

Date Range: 

 QIAGENAcceleron PharmaNovavaxargenxNeurocrine Biosciences
SymbolNYSE:QGENNASDAQ:XLRNNASDAQ:NVAXNASDAQ:ARGXNASDAQ:NBIX
Price Information
Current Price$53.38$178.75$141.86$278.96$80.69
50-Day Moving Average$53.55$175.42$173.12$295.57$94.98
52-Week Low$45.58$108.82$106.11$248.21$78.31
52-Week High$59.00$189.99$331.68$382.15$120.27
MarketRank™
Overall Score1.42.02.12.02.9
Analysis Score1.32.13.34.44.3
Community Score4.14.95.04.55.0
Dividend Score0.00.00.00.00.0
Ownership Score0.82.51.70.82.5
Earnings & Valuation Score0.60.60.60.02.5
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$52.13$171.29$249.60$355.38$116.47
% Upside from Price Target-2.34% downside-4.18% downside75.95% upside27.39% upside44.34% upside
Trade Information
Market Cap$12.17 billion$10.93 billion$10.73 billion$14.37 billion$7.65 billion
Beta0.230.131.280.930.74
Average Volume806,535572,7594,670,074178,240859,735
Sales & Book Value
Annual Revenue$1.87 billion$92.52 million$475.60 million$41.60 million$1.05 billion
Price / Sales6.51118.1522.55345.457.32
Cashflow$3.22 per shareN/AN/AN/A$4.66 per share
Price / Cash16.58N/AN/AN/A17.32
Book Value$13.22 per share$11.74 per share$6.10 per share$32.92 per share$14.19 per share
Price / Book4.0415.2323.268.475.69
Profitability
Net Income$359.19 million$-166.03 million$-418.26 million$-604.19 million$407.30 million
EPS$2.56($4.21)($14.81)($7.43)$4.57
Trailing P/E Ratio20.85N/AN/AN/A17.66
Forward P/E Ratio26.96N/A5.18N/A25.86
P/E Growth1.89N/AN/AN/AN/A
Net Margins26.61%-226.01%-89.31%-73.28%41.59%
Return on Equity (ROE)20.71%-32.11%-149.66%-24.48%35.89%
Return on Assets (ROA)10.20%-29.45%-45.23%-20.69%23.55%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.52N/A0.70N/A0.25
Current Ratio1.9012.141.2411.744.45
Quick Ratio1.5812.141.2411.504.34
Ownership Information
Institutional Ownership Percentage52.02%90.35%52.77%55.23%95.30%
Insider Ownership Percentage9.00%1.70%2.10%N/A4.30%
Miscellaneous
Employees5,610312375336845
Shares Outstanding227.99 million61.16 million75.61 million51.52 million94.87 million
Next Earnings Date2/8/2022 (Estimated)2/24/2022 (Estimated)3/7/2022 (Estimated)3/3/2022 (Estimated)2/3/2022 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
15 Best Stocks to Buy for 2022 According to Analysts15 Best Stocks to Buy for 2022 According to Analysts
finance.yahoo.com - December 6 at 12:43 PM
Heres Why Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt ResponsiblyHere's Why Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt Responsibly
nasdaq.com - December 3 at 12:59 PM
Neurocrine Biosciences (NASDAQ:NBIX) Cut to "Sell" at Zacks Investment ResearchNeurocrine Biosciences (NASDAQ:NBIX) Cut to "Sell" at Zacks Investment Research
marketbeat.com - December 2 at 2:30 AM
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific OfficerNeurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
finance.yahoo.com - November 30 at 4:41 PM
Neurocrine Biosciences (NASDAQ:NBIX) Hits New 52-Week Low at $83.66Neurocrine Biosciences (NASDAQ:NBIX) Hits New 52-Week Low at $83.66
americanbankingnews.com - November 30 at 12:44 PM
Neurocrine Biosciences, Inc. Shares Near 52-Week Low - Market MoverNeurocrine Biosciences, Inc. Shares Near 52-Week Low - Market Mover
nasdaq.com - November 30 at 6:40 AM
Neurocrine Biosciences Enters Oversold Territory (NBIX)Neurocrine Biosciences Enters Oversold Territory (NBIX)
nasdaq.com - November 29 at 5:47 PM
Thinking Of Selling Neurocrine Biosciences Inc. (NASDAQ: NBIX) Stock? Check This Out FirstThinking Of Selling Neurocrine Biosciences Inc. (NASDAQ: NBIX) Stock? Check This Out First
stocksregister.com - November 27 at 1:16 PM
Reviewing Sutro Biopharma (NASDAQ:STRO) & Neurocrine Biosciences (NASDAQ:NBIX)Reviewing Sutro Biopharma (NASDAQ:STRO) & Neurocrine Biosciences (NASDAQ:NBIX)
americanbankingnews.com - November 26 at 7:12 PM
Neurocrine Biosciences Gets Promising Drugs in Licensing DealNeurocrine Biosciences Gets Promising Drugs in Licensing Deal
gurufocus.com - November 24 at 12:01 PM
Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric DisordersNeurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders
contractpharma.com - November 22 at 2:29 PM
Neurocrine stocks up on a biotechs psychiatric drugsNeurocrine stocks up on a biotech's psychiatric drugs
biopharmadive.com - November 22 at 2:29 PM
Neurocrine Commits $2.6 Billion+ to Sosei Heptares, Neuropsychiatric DisordersNeurocrine Commits $2.6 Billion+ to Sosei Heptares, Neuropsychiatric Disorders
pharmalive.com - November 22 at 2:29 PM
Neurocrine Partners with Japanese Firm on Potential New Dementia DrugNeurocrine Partners with Japanese Firm on Potential New Dementia Drug
sdbj.com - November 22 at 2:29 PM
Neurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week Low at $84.53Neurocrine Biosciences (NASDAQ:NBIX) Sets New 52-Week Low at $84.53
americanbankingnews.com - November 22 at 1:02 PM
Neurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targetsNeurocrine pens $2.6B biobucks pact with Sosei Heptares for next-gen neuro targets
fiercebiotech.com - November 22 at 9:29 AM
Sosei Reaches Deal With Neurocrine On Neuropsychiatric Disorders; Eligible To Receive Up To $2.6 BlnSosei Reaches Deal With Neurocrine On Neuropsychiatric Disorders; Eligible To Receive Up To $2.6 Bln
markets.businessinsider.com - November 22 at 9:29 AM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of "Buy" by AnalystsNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - November 22 at 4:16 AM
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Zacks Investment ResearchNeurocrine Biosciences (NASDAQ:NBIX) Upgraded at Zacks Investment Research
marketbeat.com - November 20 at 1:24 AM
First Week of NBIX January 2022 Options TradingFirst Week of NBIX January 2022 Options Trading
nasdaq.com - November 19 at 5:39 PM
Neurocrine Biosciences (NASDAQ:NBIX) Receives New Coverage from Analysts at BMO Capital MarketsNeurocrine Biosciences (NASDAQ:NBIX) Receives New Coverage from Analysts at BMO Capital Markets
americanbankingnews.com - November 18 at 7:58 PM
Analyst Ratings For Neurocrine BiosciencesAnalyst Ratings For Neurocrine Biosciences
markets.businessinsider.com - November 17 at 12:42 PM
Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Overweight at JPMorgan Chase & Co.Neurocrine Biosciences (NASDAQ:NBIX) Rating Increased to Overweight at JPMorgan Chase & Co.
americanbankingnews.com - November 17 at 9:04 AM
Tag: Neurocrine Biosciences Inc.Tag: Neurocrine Biosciences Inc.
stocksregister.com - November 3 at 1:07 PM
What 5 Analyst Ratings Have To Say About Neurocrine BiosciencesWhat 5 Analyst Ratings Have To Say About Neurocrine Biosciences
benzinga.com - November 2 at 8:50 PM
Notable Two Hundred Day Moving Average Cross - NBIXNotable Two Hundred Day Moving Average Cross - NBIX
nasdaq.com - November 2 at 3:50 PM
Neurocrine Reports Rising Earnings, Record Sales for IngrezzaNeurocrine Reports Rising Earnings, Record Sales for Ingrezza
sdbj.com - November 2 at 3:50 PM
DateCompanyBrokerageAction
12/2/2021argenxKepler Capital Markets
Upgrade
11/29/2021argenxPiper Sandler
Upgrade
11/26/2021QIAGENKepler Capital Markets
Downgrade
11/18/2021Neurocrine BiosciencesBMO Capital Markets
Initiated Coverage
11/17/2021Neurocrine BiosciencesJPMorgan Chase & Co.
Upgrade
11/2/2021Neurocrine BiosciencesCitigroup
Lower Price Target
11/2/2021Neurocrine BiosciencesRaymond James
Lower Price Target
11/2/2021Neurocrine BiosciencesRoyal Bank of Canada
Lower Price Target
11/2/2021Neurocrine BiosciencesMizuho
Boost Price Target
11/2/2021Neurocrine BiosciencesCantor Fitzgerald
Boost Price Target
10/28/2021argenxGuggenheim
Upgrade
10/28/2021argenxRaymond James
Upgrade
10/21/2021QIAGENNorddeutsche Landesbank
Reiterated Rating
10/19/2021argenxBarclays
Upgrade
10/18/2021Neurocrine BiosciencesSVB Leerink
Reiterated Rating
10/14/2021QIAGENRedburn Partners
Initiated Coverage
10/14/2021Neurocrine BiosciencesMorgan Stanley
Downgrade
10/6/2021Acceleron PharmaJefferies Financial Group
Initiated Coverage
10/6/2021argenxJefferies Financial Group
Initiated Coverage
10/4/2021Acceleron PharmaRaymond James
Downgrade
10/4/2021argenxRobert W. Baird
Boost Price Target
10/1/2021Acceleron PharmaMorgan Stanley
Reiterated Rating
10/1/2021Acceleron PharmaBarclays
Downgrade
9/30/2021Acceleron PharmaCowen
Downgrade
9/30/2021Acceleron PharmaMorgan Stanley
Downgrade
9/30/2021Acceleron PharmaHC Wainwright
Downgrade
9/30/2021Acceleron PharmaPiper Sandler
Downgrade
9/30/2021Acceleron PharmaSVB Leerink
Boost Price Target
9/30/2021Neurocrine BiosciencesHC Wainwright
Reiterated Rating
9/27/2021Acceleron PharmaRoyal Bank of Canada
Boost Price Target
9/23/2021argenxRedburn Partners
Upgrade
9/22/2021Neurocrine BiosciencesNeedham & Company LLC
Initiated Coverage
9/7/2021argenxMorgan Stanley
Downgrade
9/2/2021argenxBarclays
Reiterated Rating
9/1/2021NovavaxChardan Capital
Reiterated Rating
8/6/2021Neurocrine BiosciencesCanaccord Genuity
Downgrade
8/5/2021Acceleron PharmaPiper Sandler
Boost Price Target
8/4/2021argenxJPMorgan Chase & Co.
Reiterated Rating
8/4/2021Neurocrine BiosciencesMorgan Stanley
Lower Price Target
8/3/2021argenxMorgan Stanley
Boost Price Target
7/23/2021argenxDeutsche Bank Aktiengesellschaft
Initiated Coverage
7/22/2021argenxWedbush
Boost Price Target
7/21/2021argenxHC Wainwright
Reiterated Rating
7/19/2021Acceleron PharmaWolfe Research
Initiated Coverage
7/16/2021Neurocrine BiosciencesHC Wainwright
Reiterated Rating
7/14/2021QIAGENCheuvreux
Downgrade
7/14/2021QIAGENKepler Capital Markets
Downgrade
7/14/2021QIAGENCitigroup
Lower Price Target
7/9/2021QIAGENKepler Capital Markets
Upgrade
6/27/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/25/2021QIAGENDZ Bank
Reiterated Rating
6/24/2021Acceleron PharmaOppenheimer
Boost Price Target
6/18/2021argenxUBS Group
Initiated Coverage
6/17/2021QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
6/15/2021Acceleron PharmaSVB Leerink
Reiterated Rating
6/15/2021NovavaxCantor Fitzgerald
Boost Price Target
6/11/2021QIAGENBerenberg Bank
Reiterated Rating
6/8/2021QIAGENThe Goldman Sachs Group
Reiterated Rating
6/8/2021argenxWedbush
Lower Price Target
6/7/2021argenxPiper Sandler
Lower Price Target
6/3/2021QIAGENThe Goldman Sachs Group
Initiated Coverage
5/18/2021NovavaxJPMorgan Chase & Co.
Reiterated Rating
5/18/2021argenxMorgan Stanley
Boost Price Target
5/18/2021Neurocrine BiosciencesThe Goldman Sachs Group
Initiated Coverage
5/16/2021argenxKepler Capital Markets
Downgrade
5/12/2021NovavaxB. Riley
Lower Price Target
5/12/2021NovavaxCantor Fitzgerald
Lower Price Target
5/12/2021NovavaxHC Wainwright
Lower Price Target
5/12/2021NovavaxJPMorgan Chase & Co.
Downgrade
5/11/2021NovavaxJefferies Financial Group
Lower Price Target
5/10/2021argenxHC Wainwright
Upgrade
5/6/2021Neurocrine BiosciencesWedbush
Lower Price Target
5/6/2021Neurocrine BiosciencesOppenheimer
Lower Price Target
5/6/2021Neurocrine BiosciencesMorgan Stanley
Lower Price Target
5/6/2021Neurocrine BiosciencesSVB Leerink
Lower Price Target
5/6/2021Neurocrine BiosciencesBarclays
Upgrade
5/4/2021QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
5/3/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/26/2021Neurocrine BiosciencesMizuho
Lower Price Target
4/23/2021argenxRedburn Partners
Initiated Coverage
4/22/2021QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
4/19/2021argenxMorgan Stanley
Lower Price Target
4/19/2021Neurocrine BiosciencesMorgan Stanley
Boost Price Target
4/12/2021Neurocrine BiosciencesWedbush
Lower Price Target
4/7/2021QIAGENDZ Bank
Reiterated Rating
4/2/2021QIAGENKepler Capital Markets
Reiterated Rating
4/1/2021QIAGENDZ Bank
Reiterated Rating
3/29/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/29/2021Acceleron PharmaSVB Leerink
Reiterated Rating
3/23/2021Acceleron PharmaSVB Leerink
Downgrade
3/22/2021Acceleron PharmaThe Goldman Sachs Group
Reiterated Rating
3/12/2021NovavaxHC Wainwright
Boost Price Target
3/11/2021Acceleron PharmaWolfe Research
Initiated Coverage
3/8/2021argenxMorgan Stanley
Boost Price Target
3/5/2021argenxKepler Capital Markets
Reiterated Rating
3/5/2021Neurocrine BiosciencesRobert W. Baird
Reiterated Rating
3/1/2021Acceleron PharmaCitigroup
Boost Price Target
2/26/2021Acceleron PharmaPiper Sandler
Boost Price Target
2/26/2021Acceleron PharmaMorgan Stanley
Boost Price Target
2/26/2021Acceleron PharmaSVB Leerink
Boost Price Target
2/19/2021QIAGENBerenberg Bank
Reiterated Rating
2/17/2021QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
2/10/2021QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
2/5/2021NovavaxCantor Fitzgerald
Boost Price Target
2/1/2021NovavaxB. Riley
Boost Price Target
1/29/2021Acceleron PharmaJPMorgan Chase & Co.
Boost Price Target
1/29/2021NovavaxCantor Fitzgerald
Boost Price Target
1/6/2021QIAGENNorddeutsche Landesbank
Reiterated Rating
1/6/2021QIAGENNord/LB
Reiterated Rating
12/14/2020QIAGENDZ Bank
Reiterated Rating
12/14/2020NovavaxJefferies Financial Group
Initiated Coverage
12/10/2020QIAGENExane BNP Paribas
Reiterated Rating
12/9/2020QIAGENDeutsche Bank Aktiengesellschaft
Reiterated Rating
11/17/2020NovavaxHC Wainwright
Lower Price Target
10/22/2020NovavaxB. Riley
Lower Price Target
8/17/2020NovavaxB. Riley
Reiterated Rating
8/5/2020NovavaxLADENBURG THALM/SH SH
Downgrade
8/5/2020NovavaxJPMorgan Chase & Co.
Upgrade
7/16/2020NovavaxB. Riley
Boost Price Target
7/16/2020NovavaxHC Wainwright
Boost Price Target
7/8/2020NovavaxLADENBURG THALM/SH SH
Reiterated Rating
7/7/2020NovavaxCantor Fitzgerald
Boost Price Target
6/29/2020NovavaxB. Riley
Boost Price Target
6/29/2020NovavaxHC Wainwright
Boost Price Target
6/19/2020NovavaxCantor Fitzgerald
Boost Price Target
(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.